×
Hero Background

Glioblastoma Multiforme Companies

ID: MRFR/HC/10640-HCR
128 Pages
Rahul Gotadki
October 2025

Glioblastoma multiforme (GBM) is a highly aggressive type of brain cancer. Companies involved in glioblastoma research and treatment focus on developing therapies, diagnostic tools, and technologies to improve patient outcomes.

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Glioblastoma Multiforme Market Research Report—Global Forecast till 2035 Infographic
Summary Table of Contents Segmentation Download PDF

Top Industry Leaders in the Glioblastoma Multiforme Market

Glioblastoma Multiforme Key Companies

 

Latest Glioblastoma Multiforme Companies Update


In December 2022, the FDA granted Fast Track designation to WP1122, a novel glioblastoma treatment developed by Wolf Pharmaceuticals. This designation expedites the review process for promising new drugs, potentially bringing WP1122 to market sooner.


In November 2023, the China National Medical Products Administration (NMPA) granted marketing approval for the Optune device from NovoCure. This non-invasive therapy uses tumor treating fields (TTF) to disrupt cancer cell division and is a valuable addition to the treatment landscape for GBM patients in China.


In October 2023, Roche announced positive Phase 2 results for RO7499870, a targeted therapy aimed at a specific genetic mutation found in some GBM tumors. These results pave the way for further development of this promising treatment candidate.


List of Glioblastoma Multiforme Key Companies in the Market



  • Merck & Co., Inc (US)

  • Amgen, Inc (US)

  • Bristol-Myers Squibb Company (US)

  • Hoffmann-La Roche Ltd (Switzerland)

  • Novartis AG (Switzerland)

  • Pfizer Inc (US)

  • AstraZeneca (UK)

  • Eli Lilly and Company (US)

  • VBI Vaccines Inc. (US)

  • AbbVie Inc. (US)